Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03326973 · ClinicalTrials.gov registry record
Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 107
- Enrollment target
NCT03326973: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03326973 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 107 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03326973 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 107 participants
- Enrollment target
Study Summary
To identify and describe long-term quality of life (QOL) issues in patients with metastatic melanoma treated with checkpoint inhibitors who achieved cancer control for a minimum of 12 months and remain on maintenance checkpoint inhibitor therapy.
Primary Outcome
On the EQ-5D-3L, respondents are asked to indicate their health state by marking the box associated with the most appropriate statement in each of the 5 dimensions, resulting in a one digit number expressing the level (1-3) selected for that dimension from no problems to extreme problems.
Interventions
- BEHAVIORAL EuroQoL EQ-5D-3L
- BEHAVIORAL EORTC QLQ-C30
- OTHER PRO-CTCAE
- BEHAVIORAL Fatigue severity score questionnaire
- BEHAVIORAL The COST
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2020-12-14 |
What the finished NCT03326973 record still lists
NCT03326973 is an observational study that tracks outcomes without assigning an intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 5 interventions - of which EuroQoL EQ-5D-3L is the first listed.
NCT03326973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03326973 about?
NCT03326973 is a clinical study titled "Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors". To identify and describe long-term quality of life (QOL) issues in patients with metastatic melanoma treated with checkpoint inhibitors who achieved cancer control for a minimum of 12 months and remain on maintenance checkpoint inhibitor therapy.
What is the current status of trial NCT03326973?
This trial is currently completed. The enrollment target is 107 participants. The study started on 2017-10-25. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT03326973?
The interventions under investigation include: EuroQoL EQ-5D-3L (BEHAVIORAL), EORTC QLQ-C30 (BEHAVIORAL), PRO-CTCAE (OTHER), Fatigue severity score questionnaire (BEHAVIORAL), The COST (BEHAVIORAL).
Who is sponsoring clinical trial NCT03326973?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI